Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | V600M |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | BRAF V600M (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600M results in intermediate Braf kinase activity in cell culture (PMID: 28783719), and in one of two cell lines increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and therefore, is predicted to lead to a gain of Braf protein function. |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF V600M BRAF mutant BRAF V600X BRAF V600M |
Transcript | NM_004333.6 |
gDNA | chr7:g.140753337C>T |
cDNA | c.1798G>A |
Protein | p.V600M |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004333 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03839342 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) | Active, not recruiting | CAN | 0 |
NCT04061980 | Phase II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Nivolumab | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | Active, not recruiting | USA | 0 |